Seer seizure forecasting research published in Lancet Neurology

Seer team members, Pip Karoly, Dean Freestone and Mark Cook have had their research published in Lancet Neurology.

Epilepsy has long been suspected to be governed by cyclic rhythms, with seizure rates rising and falling periodically over weeks, months, or even years.

The very long scales of seizure patterns seem to defy natural explanation and have sometimes been attributed to hormonal cycles or environmental factors.

The research aimed to quantify the strength and prevalence of seizure cycles at multiple temporal scales across a large cohort of people with epilepsy.

It was the largest study of seizure cycles in humans in the world, and the first to provide conclusive evidence that multi-day cycles exist for most people with epilepsy.

Read Pip Karoly’s article in The Pursuit for more about how the study findings should be applied to improve the management, treatment and care of people with epilepsy.

Seer is a finalist in the 2018 Telstra Business Awards!

Seer is one of only 84 finalists in the 2018 Telstra Business Awards. 

The prestigious program recognises the best in business across four categories: Emerging and Energised, Small and Succeeding, Medium and Making Waves, and Social Change Maker.

Seer, one of over 10,000 entries in this years awards, was evaluated across a broad range of criteria, including: strategy and vision, customers and marketing, operations, people and culture, innovation and technology, social responsibility and financial acumen.

State winners will be announced at a celebratory dinner in August, with National winners announced in September. 

Wish us luck! 

You can read more about the awards and the other finalists here

Breakthrough epilepsy monitoring device receives investment funding

Seer Medical's Mark Cook, in conjunction with The Bionics Institute, St Vincent's Melbourne and the University of Melbourne has launched a new Australian venture to develop a breakthrough monitoring device to improve management of epilepsy and seizure-related conditions – Minder ™.

The successful venture with an initial A$3.65 million investment from Cochlear Ltd and other Australian investors is a culmination of a decade of research and development into improving outcomes for Epilepsy sufferers and has been led by Seer Director, Prof Mark Cook and A/Prof Chris Williams from the Bionics Institute.

Read more about the device on the Bionics Institute website here.